Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
Markus Borner(University of Bern), Walter Mingrone(Kantonsschule Olten), Andreas Trojan(Immunologie-Zentrum Zürich), Roger von Moos(Kantonsspital Graubünden), Damien Dietrich(University Hospital of Bern), Piercarlo Saletti(Institute of Oncology Research), Viviane Hess(University Hospital of Bern), Doris Lanz(Queen Mary University of London), Андреас Каппелер(University Hospital of Bern), Dieter Koeberle(Kantonsspital St. Gallen), Daniel Helbling(University Hospital of Bern), A. Roth(University Hospital of Zurich), Bernhard C. Pestalozzi(University of Zurich), Thomas Ruhstaller(University Hospital Bonn), Clemens B. Caspar(Kantonsspital Baden), Daniel Rauch(Washington University in St. Louis)
Cited by 129
Related Papers
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684
Comparison of Orally Administered Cannabis Extract and Delta-9-Tetrahydrocannabinol in Treating Patients With Cancer-Related Anorexia-Cachexia Syndrome: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial From the Cannabis-In-Cachexia-Study-Group
|Journal of Clinical Oncology|2006|409